#Aids2026: Bhekisisa analysed SA’s first LEN roll-out data. Here's what it found

IOL (Independent Online)Party-alignedCenter3 hr. ago

The Western Cape Department of Health and Wellness reported that nearly 88% of individuals receiving the lenacapavir injection for HIV prevention were first-time users of long-acting HIV prevention methods. Administered between June 8 and July 24 across 22 public health facilities, 2,339 lenacapavir injections were given, with 2,049 being first-time users. The drug, which is not a vaccine but an effective prevention method, offers a monthly alternative to daily oral PrEP, which has been available since 2016. MEC for Health and Wellness Mireille Wenger highlighted the significance of providing more choices in HIV prevention, noting that the convenience of the injectable form helps overcome barriers such as daily medication adherence. The program has seen strong uptake among high-risk groups, including pregnant women, with notable numbers at specific clinics focused on adolescent girls and young women.

Bias read (Center): The article presents information about the rollout of lenacapavir as a public health initiative without overtly favoring any political ideology. It focuses on factual data provided by the Western Cape Department of Health and quotes officials like MEC Mireille Wenger to explain the program's impact.

Mail & GuardianIndependentCenteryesterday

An article published by Bhekisisa analyzes the rollout of lenacapavir (LEN), an HIV prevention injection, in South Africa. According to data presented at the International Aids Conference, nearly half of all HIV prevention injection users in Africa live in South Africa, with 31,297 users registered as of June 2026. The health department began distributing the injection at 360 government clinics across six provinces on June 5, and 98.5% of those offered a choice between a daily pill and the injection opted for the latter. Most users are concentrated in Gauteng and KwaZulu-Natal, which together account for nearly half of South Africa's population. Health Minister Aaron Motsoaledi noted concerns about vaccine hesitancy but emphasized that data shows acceptance of LEN. The injection provides six months of protection and requires a follow-up shot, with some users needing additional tablets if they miss the follow-up window. Early results from an implementation study suggest high adherence among participants.

Bias read (Center): The article presents factual data and quotes from the health minister without overt ideological slant. While it discusses government action and public health outcomes, it does not favor one political perspective over another. The framing remains neutral, focusing on the effectiveness and rollout ofa